Saturday 17 October 2026
Export BCLI’s income statement to Excel — free account
Brainstorm Cell Therapeutics Inc.
BCLI Healthcare Biotechnology
In the quarter to June 2026, EPS fell 2.94%, free cash flow grew 74.4% and total debt rose 1,148.5%, each against the same quarter a year earlier.
0.78
0.02
−2.50%
Follow BCLI
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 28.50 | 37.20 | 43.20 | 49.65 | 57.00 | 41.25 | 16.35 | 1.95 | 1.05 | 0.52 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 58.05 | 77.70 | 80.25 | 67.50 | 269.25 | 122.10 | 70.50 | 51.90 | 11.85 | 2.37 | |||||
| People | |||||||||||||||
| People | Employees | 22 | 24 | 31 | 32 | 40 | 43 | 43 | 29 | 27 | 20 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (5) | (5) | (14) | (23) | (32) | (24) | (24) | (17) | (12) | (10) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (5) | (5) | (14) | (23) | (32) | (24) | (24) | (17) | (12) | (10) | |||||
| Depreciation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (4.05) | (3.90) | (10.49) | (15.89) | (16.04) | (10.19) | (9.90) | (6.00) | (2.31) | (1.11) | |||||
| Cash flow | (4.71) | (1.89) | (9.29) | (7.70) | (17.68) | (10.88) | (7.93) | (7.12) | (1.81) | (0.75) | |||||
| Capex | (0.08) | (0.14) | (0.28) | (0.32) | (0.19) | (0.14) | (0.01) | (0.01) | 0.00 | 0.00 | |||||
| Free cash flow | (4.79) | (2.03) | (9.56) | (8.02) | (17.87) | (11.02) | (7.95) | (7.13) | (1.81) | (0.75) | |||||
| Book value | 7.95 | 4.70 | 3.76 | (8.37) | 17.81 | 8.01 | (1.24) | (1.69) | (1.55) | (1.08) | |||||
| Shares, m | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 5 | 9 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (6) | (2) | (12) | (11) | (35) | (26) | (19) | (20) | (9) | (7) | ||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | |||||
| Free cash flow | (6) | (3) | (13) | (12) | (36) | (27) | (19) | (20) | (9) | (7) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 10 | 4 | 4 | (14) | 32 | 17 | (6) | (6) | (9) | (11) | ||||
| Total debt | — | — | — | 1 | 3 | 1 | 1 | — | 0 | 1 | |||||
| Net debt | (10) | (8) | (7) | 1 | (39) | (21) | (2) | (1) | 0 | 1 | |||||
| Shareholders’ equity | 10 | 6 | 5 | (12) | 35 | 19 | (3) | (5) | (8) | (10) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (35.78) | (44.63) | (123.16) | (261.83) | (110.09) | (60.74) | (128.69) | (271.62) | (384.87) | (722.28) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (41.46) | (62.76) | (256.02) | 645.29 | (273.75) | (89.25) | (297.38) | 436.73 | 184.17 | 116.14 | |||||
Negative figures in brackets.
Charts ten years each
Brainstorm Cell Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CALC CalciMedica Inc. | $7.4M | — (loss-making) | — | — | n/m | +31.42% (above 0%: growing) | 0.00% | 0.00% | Compare |
| XCUR Exicure, Inc. | $7.3M | — (loss-making) | — (loss-making) | −80.51% (below 0%: shrinking) | n/m | +65.38% (above 0%: growing) | 100.00% | 0.00% | Compare |
| SKYE Skye Bioscience, Inc. | $7.0M | — (loss-making) | — | −34.71% (below 0%: shrinking) | n/m | +34.84% (above 0%: growing) | 72.71% | 0.00% | Compare |
| BCLI Brainstorm Cell Therapeutics Inc. | $7.0M | — (loss-making) | — | — | n/m | +74.44% (above 0%: growing) | 0.00% | 0.00% | |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR | $7.0M | — (loss-making) | — (loss-making) | −39.66% (below 0%: shrinking) | n/m | +5.08% (above 0%: growing) | (422.22%) | (2,437.96%) | Compare |
| NIKI Niki BioSolutions, Inc. | $6.9M | — (loss-making) | 31.9× | −32.36% (below 0%: shrinking) | +69.51% (above 0%: growing) | +58.14% (above 0%: growing) | (154.22%) | 0.00% | Compare |
| AIM AIM ImmunoTech Inc. | $6.8M | — (loss-making) | — (loss-making) | +4.00% (above 0%: growing) | n/m | −167.46% (below 0%: shrinking) | 80.77% | (13,511.54%) | Compare |
| SYBX Synlogic, Inc. | $6.7M | — (loss-making) | — (loss-making) | −95.40% (below 0%: shrinking) | n/m | −277.87% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| FBLG FibroBiologics Inc. | $6.7M | — (loss-making) | — | — | n/m | +21.59% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $6.9M | — | — | −37.18% | — | +26.51% | 72.71% | 0.00% |
Brainstorm Cell Therapeutics Inc. (BCLI) key facts
- Brainstorm Cell Therapeutics Inc. (BCLI) is a Biotechnology company in the Healthcare sector.
- As of October 16, 2026, BCLI traded at $0.78, a market capitalization of $7.0 million.
- Return on equity was 116.1% and debt-to-equity -0.11.